NR4A1 and breast carcinoma: These drugs now represent the standard of care for hormone receptor (HR)-positive, human epidermal growth factor receptor (HER) 2-negative locally advanced and metastatic breast cancer, in combination with endocrine therapy (ET), which represents the largest subgroup of breast cancer.